Erudio Healtherudio.com
Drug
HB1801 trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying HB1801: Neo-Healer. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Neo-Healer NCT06747338 · Shanghai JMT-Bio Inc. | early or locally advanced HER2-positive breast cancer | Phase 3 | 104 | 21 | Focused | Nov 20, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| HEALER NCT05838066 · Shanghai JMT-Bio Inc. FocusedView → | first-line HER2-positive recurrent or metastatic breast cancer | Phase 3 | Focused | View | |||